IBRX
ImmunityBio, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-14.03
P/S
64.25
EV/EBITDA
-36.09
DCF Value
$-23.84
FCF Yield
-4.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.4%
Operating Margin
-226.0%
Net Margin
-310.2%
ROE
64.3%
ROA
-70.0%
ROIC
-56.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $38.3M | $-61.9M | $-0.06 |
| FY 2025 | $113.3M | $-351.4M | $-0.38 |
| Q3 2025 | $32.1M | $-67.3M | $-0.07 |
| Q2 2025 | $26.4M | $-92.6M | $-0.10 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllLatest News
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.06
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.